Handbook of COVID-19 Prevention and Treatment

The First Affiliated Hospital, Zhejiang University School of Medicine
Compiled According to Clinical Experience
https://drive.google.com/file/d/1n53q1dDHEQoU_PBLzyaMfou9mEMy2NrH/view

AP exams affected by COVID-19

Students remain eager to take AP Exams and have a chance to earn credit and placement. We surveyed 18,000 AP students and 91% indicated they want to complete this important step, urging us not to cancel this opportunity.

The AP Program will invest heavily over the next month in the following ways:

•
For the 2019-20 exam administration only, students can take a 45-minute online exam at home. Educator-led development committees are currently selecting the exam questions that will be administered.

•
Some students may want to take the exam sooner rather than later, while the content is still fresh. Other students may want more time to practice. For each AP subject, there will be two different testing dates.

•
AP curricula are locally developed and we defer to local decisions on how best to help students complete coursework. To be fair to all students, some of whom have lost more instructional time than others, the exam will only include topics and skills most AP teachers and students have already covered in class by early March.

•
Colleges support this solution and are committed to ensuring that AP students receive the credit they've worked this year to earn. For decades, colleges have accepted a shortened AP Exam for college credit when groups of students have experienced emergencies.

•
Students will be able to take these streamlined exams on any device they have access to—computer, tablet, or smartphone. Taking a photo of handwritten work will also be an option.

•
We recognize that the digital divide could prevent some low-income and rural students from participating. Working with partners, we'll invest so these students have the tools and connectivity they need to review AP content online and take the exam. If your students need mobile tools or connectivity, you can reach us directly to let us know.

•
The exam questions are designed in ways that prevent cheating. We use a range of digital security tools and techniques, including plagiarism detection software, to protect the integrity of the exams. Scoring at-home work for an AP Exam isn't new to the AP Program. For years the AP Program has received and scored at-home student work as part of the exams for the AP Computer Science Principles and AP Capstone™ courses.

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

https://www.nature.com/articles/s41421-020-0153-3?fbclid=IwAR1HlP-FZeEMbdyx4NKc7iySzIpPTABFhL92JGoKSQQDFoHOEwleP_E8BkY

Сначала напишу, какой сухой остаток:
Мелатонин может быть возможным лекарством от COVID-19, потому что мелатонин снижает экспрессию гена АСЕ2. АСЕ2 рецепторы - это те самые рецепторы, к которым присоединяется имеющийся в настоящий момент коронавирус, для того, чтобы попасть в клетку. Если вирус не может попасть в клетку, он не может размножаться.

Abstract
Human coronaviruses и(HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the “Complementary Exposure” pattern: the targets of the drugs both hit the HCoV–host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.

The Coronavirus Explained & What You Should Do (a very good animation)

Watch on YouTube